COR - Cencora, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $358.14 DETAILS

Stock News

Why Cencora (COR) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Sep 07, 2026 06:45 AM • zacks.com

Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.

Sep 04, 2026 12:46 PM • zacks.com

Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?

Cencora (COR) reported earnings 30 days ago. What's next for the stock?

Sep 04, 2026 08:36 AM • zacks.com

Cencora Launches Cell and Gene Therapy Enablement for Health Systems

COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.

Sep 04, 2026 06:56 AM • zacks.com

Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen

Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.

Sep 03, 2026 12:56 PM • zacks.com

Cencora's Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies. “Cell and gene therapies have the potential to transform care for patients with serious and compl.

Sep 02, 2026 04:30 AM • businesswire.com

Connor Clark & Lunn Investment Management Ltd. Invests $841,000 in Cencora, Inc. $COR

Connor Clark and Lunn Investment Management Ltd. acquired a new stake in shares of Cencora, Inc. (NYSE: COR) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,973 shares of the company's stock, valued at approximately $841,000. Several other

Aug 31, 2026 01:13 AM • defenseworld.net

Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance

Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.

Aug 23, 2026 10:22 AM • seekingalpha.com

Advisors Capital Management LLC Takes $748,000 Position in Cencora, Inc. $COR

Advisors Capital Management LLC purchased a new stake in shares of Cencora, Inc. (NYSE: COR) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,644 shares of the company's stock, valued at approximately $748,000. Several other hedge funds and

Aug 21, 2026 11:10 PM • defenseworld.net

"Trumpflation" Is Real -- and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

These healthcare companies can actually benefit from inflation.

Aug 19, 2026 03:50 AM • fool.com

Why Cencora (COR) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Aug 12, 2026 06:41 AM • zacks.com

Cencora, Inc. (NYSE:COR) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Cencora, Inc. (NYSE: COR - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year

Aug 11, 2026 10:15 PM • defenseworld.net

Why Cencora (COR) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Aug 11, 2026 06:50 AM • zacks.com

Here's Why Cencora (COR) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Aug 10, 2026 06:46 AM • zacks.com

Allspring Growth Fund Q2 2026 Performance Update

Allspring Growth Fund outperformed the Russell 3000 Growth Index during the quarter. Sandisk Corp. is riding the AI storage super-cycle. Shares of Cencora could not distribute in a 'risk-on' market.

Aug 06, 2026 04:15 AM • seekingalpha.com

Cencora Q3 Earnings Call Highlights

Cencora NYSE: COR reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook.

Aug 06, 2026 03:05 AM • marketbeat.com

Cencora, Inc. (COR) Q3 2026 Earnings Call Transcript

Aug 05, 2026 12:00 PM • seekingalpha.com

Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins

Cencora Inc. (NYSE:COR) on Wednesday reported third-quarter adjusted earnings of $4.48 per share, beating the consensus of $4.35.

Aug 05, 2026 08:44 AM • benzinga.com

COR Stock Gains as Q3 Earnings Beat on Segment Growth, EPS View Raised

Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.

Aug 05, 2026 07:51 AM • zacks.com

Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Aug 05, 2026 06:31 AM • zacks.com